✨ Free AI Report
BeOne Medicines AG: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research BeOne Medicines AG
Company Research

BeOne Medicines AG: Business Overview, Financials & Competitive Analysis

BeOne Medicines AG scores 8/10 on the AskCyborg Cyborg Score (Strong). BeOne Medicines maintains Strong Buy as Brukinsa and Tevimbra drive robust growth and pipeline catalysts approach. The company demonstrated exceptional revenue growth of 55% year-over-year to $3.81 billion in 2024. Operating losses improved significantly, declining 27% to $644.79 million. Strong analyst support and expanding global commercialization underpin confidence.

What is BeOne Medicines AG's industry? BeOne Medicines AG (beone.com) operates in Biopharmaceutical/Oncology. AskCyborg classifies BeOne Medicines AG under Biopharmaceutical/Oncology in its company registry.

BeOne Medicines AG (formerly BeiGene) is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. The company achieved $3.81 billion in revenue in 2024, representing 55...

8/ 10Strong

Cyborg Score thesis

BeOne Medicines maintains Strong Buy as Brukinsa and Tevimbra drive robust growth and pipeline catalysts...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Oncology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest BeOne Medicines AG Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for BeOne Medicines AG

AskCyborg analysts argue the bull and bear cases for BeOne Medicines AG across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
BeOne Medicines AG OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

BeOne Medicines AG Overview

Pro stress-test →

BeOne Medicines AG (formerly BeiGene) is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. The company achieved $3.81 billion in revenue in 2024, representing 55% growth compared to the prior year.

Strategic Profile

Pro stress-test →

With a portfolio spanning hematology and solid tumors, the company is engaged in development of a diverse pipeline of novel therapeutics. Key products include Brukinsa, an orally available BTK inhibitor, along with Tevimbra and Pamiparib. Analysts rate the stock "Strong Buy" with a 12-month price target of $370.25.

Competitive Landscape

Pro stress-test →

BeOne Medicines is focused on discovering and developing innovative cancer treatments for hematology and solid tumors worldwide. The company competes with other global oncology players through proprietary BTK inhibitors and next-generation immuno-oncology therapies across multiple tumor types.

Industry Context

BeOne Medicines AG operates in Biopharmaceutical/Oncology.

Key facts

Founded: 2010 · Headquarters: Basel, Switzerland · Revenue: $3.81B · Market cap: $200B+

What the analysts stress-tested

The top findings that survived the multi-agent debate for BeOne Medicines AG.

  • Revenue grew 55% in 2024 to $3.81 billion, demonstrating accelerating commercial traction
  • Rapid commercial expansion and operational efficiencies position the company for enhanced profitability and margin improvement
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Barclays raised price target to $394 from $385
  • February 2026Bernstein reiterated Buy rating with $414 price target
  • +1 moreTrack every material event for BeOne Medicines AG as it happens. Explore monitoring →
Get alerted when BeOne Medicines AG has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Revlimid/ImbruvicaEstablished hematologic cancer therapies→Opdivo/YervoyImmuno-oncology franchise→KeytrudaLeading checkpoint inhibitor→

Compare BeOne Medicines AG with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

BeOne Medicines AG operates in Biopharmaceutical/Oncology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical/Oncology research →
NEW · MCP server

Ask your AI assistant about BeOne Medicines AG

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare BeOne Medicines AG and its top competitor on Cyborg Score”
“What did BeOne Medicines AG do this quarter?”
“Is BeOne Medicines AG a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does BeOne Medicines AG do?+
BeOne Medicines AG (formerly BeiGene) is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. The company achieved $3.81 billion in revenue in 2024, representing 55...
What is BeOne Medicines AG's Cyborg Score?+
BeOne Medicines AG has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are BeOne Medicines AG's main competitors?+
Named competitors include Revlimid/Imbruvica, Opdivo/Yervoy, Keytruda. The full competitive landscape is in the AskCyborg report.
How can I get the full BeOne Medicines AG research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the BeOne Medicines AG research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track BeOne Medicines AG over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.8UCB SATop companies in Biopharmaceutical by Cyborg Score